



Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (1)	08/01/2022	Common Stock	111,663	\$ 0.815	D	Â
Stock Option (Right to Buy)	Â (2)	10/31/2023	Common Stock	39,878	\$ 6.8646	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sharp Shalini C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO, CA 94949	Â	Â	Â See Remarks	Â

## Signatures

By: /s/ Shalini  
Sharp

01/30/2014

Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/4th of the option shall vest one year from May 21, 2012 and then the remaining shares vest monthly until May 21, 2016, provided the Reporting Person has not terminated services with the Issuer.
- (2) 1/4th of the option shall vest one year from November 1, 2013 and then the remaining shares vest monthly until November 1, 2017, provided the Reporting Person has not terminated services with the Issuer.

Â

### Remarks:

Chief Financial Officer and Senior Vice President

### Exhibit List

Exhibit 24 - Limited Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.